Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Galectin Therapeutics Inc. Shares Jumped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Galectin Thersapeutics (NASDAQ: GALT  ) , a clinical-stage biopharmaceutical focused on developing therapies to treat fibrotic diseases and cancer, advanced as much as 12% after announcing the dosing of its first patient in the second cohort of a phase 1 study for GR-MD-02.

So what: The buzz surrounding GR-MD-02 is that it treats nonalcoholic steatohepatitis, or NASH, a serious disease characterized by fatty buildup in the liver that could affect as much as 5% of the U.S population, meaning there's a wide moat opportunity for treatment. This next dosing cohort will involve patients receiving four mg/kg of GR-MD-02, which is double the dose of the first cohort in its phase 1 dose-escalating studies. The first cohort, if you recall, demonstrated both safety and tolerability, which is the common primary endpoint of phase 1 studies.

Now what: Shareholders are certainly loving the relief rally on the heels of today's press release, but they should also realize that we haven't even hit the meat and potatoes of GR-MD-02's efficacy yet, which is what's really going to add some differentiation to this therapy. I would suggest not getting too wrapped up by the word "NASH" in any drug's indication at the moment, and would stick to the sidelines until we have top-line efficacy data from a mid-stage study.

Galectin shares may have soared today, but it'll likely have a hard time keeping pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report, "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2919988, ~/Articles/ArticleHandler.aspx, 8/31/2015 1:56:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,542.36 -100.65 -0.60%
S&P 500 1,977.38 -11.49 -0.58%
NASD 4,800.01 -28.32 -0.59%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 1:39 PM
GALT $2.30 Up +0.34 +17.27%
Galectin Therapeut… CAPS Rating: *